Skip to content

DD STOCK

Stock News & Forecast & Price target & Analyst Ratings & Estimates

  • Home
  • technology
  • Unnecessary
  • Health Care
  • Necessary
  • Financials
  • Energy
  • Industrials
  • Basic Materials
  • Telecommunications
  • Utilities
  • Toggle search form

Category: Health Care

Raymond James announces AbbVie (NYSE:ABBV) Price Target of $177

Posted on September 30, 2023 By legume No Comments on Raymond James announces AbbVie (NYSE:ABBV) Price Target of $177

Raymond James analyst Gary Nachman initiates coverage on AbbVie (NYSE:ABBV) with a Outperform rating and announces Price Target of $177.

Health Care

Pfizer Says Impact Of Tornado On Site Is Expected To Affect Supply Of Medicines From Rocky Mount Facility Until At Least Mid-2024

Posted on September 26, 2023 By legume No Comments on Pfizer Says Impact Of Tornado On Site Is Expected To Affect Supply Of Medicines From Rocky Mount Facility Until At Least Mid-2024

Pfizer Says Impact Of Tornado On Site Is Expected To Affect Supply Of Medicines From Rocky Mount Facility Until At Least Mid-2024; Begun Storing Non-Production Related Materials In A New Warehouse Secured As A Temporary Replacement To Its Hirise Warehouse

Health Care

Abbott (NYSE:ABT) Declares 399th Consecutive Quarterly Dividend

Posted on September 22, 2023 By legume No Comments on Abbott (NYSE:ABT) Declares 399th Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 399(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2023, to shareholders of record at the close of business on Oct. 13, 2023. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

Health Care

Moderna Ramps Down MRNA Drug Substance Production For Its Covid-19 Vaccine At Lonza

Posted on September 20, 2023 By legume No Comments on Moderna Ramps Down MRNA Drug Substance Production For Its Covid-19 Vaccine At Lonza

Moderna Ramps Down MRNA Drug Substance Production For Its Covid-19 Vaccine At Lonza; Will Ramp Down Production Of MRNA Drug Substance For Its Covid-19 Vaccine At Lonza’s Site In Visp, Switzerland, In Q3 2023

Health Care

Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates

Posted on September 13, 2023 By legume No Comments on Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates

Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates. While the 2023 cost of sales remains elevated, the company is currently resizing its manufacturing footprint and supply base to accelerate gross margin expansion towards its longer-term target of 75-80%.

Health Care

HSBC announces Zoetis (NYSE:ZTS) Price Target of $230

Posted on September 13, 2023 By legume No Comments on HSBC announces Zoetis (NYSE:ZTS) Price Target of $230

HSBC analyst Morten Herholdt initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $230.

Health Care

Stifel maintains Zoetis (NYSE:ZTS) $205 price target

Posted on September 13, 2023 By legume No Comments on Stifel maintains Zoetis (NYSE:ZTS) $205 price target

Stifel analyst Jonathan Block reiterates Zoetis (NYSE:ZTS) with a Buy and maintains $205 price target.

Health Care

AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab)

Posted on September 13, 2023 By legume No Comments on AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab)

AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab); The Study Met Its Primary Endpoint In Patients With Moderately To Severely Active Crohn’s Disease Who Have Failed One Or More Anti-TNFs.

Health Care

Truist Securities maintains Gilead Sciences (NASDAQ:GILD) $91 price target

Posted on September 8, 2023 By legume No Comments on Truist Securities maintains Gilead Sciences (NASDAQ:GILD) $91 price target

Truist Securities analyst Robyn Karnauskas reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $91 price target.

Health Care

B of A Securities raises Gilead Sciences (NASDAQ:GILD) price target from $88 to $95

Posted on September 8, 2023 By legume No Comments on B of A Securities raises Gilead Sciences (NASDAQ:GILD) price target from $88 to $95

B of A Securities analyst Geoff Meacham upgrades Gilead Sciences (NASDAQ:GILD) from Neutral to Buy and raises the price target from $88 to $95.

Health Care

Posts navigation

1 2 … 25 Next

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022

Categories

  • Basic Materials
  • Consumer Discretionary
  • Consumer Staples
  • Energy
  • Financials
  • Health Care
  • Industrials
  • Real Estate
  • Technology
  • Telecommunications
  • Uncategorized
  • Utilities

Recent Posts

  • Nike Exec Said Member Engagement Within DTC Business Up Double Digits Vs Last Year
  • Nike Fiscal Q1 Earnings, Revenue Rise
  • Piper Sandler lowers Accenture (NYSE:ACN) price target from $312 to $300
  • Deutsche Bank raises Nike (NYSE:NKE) price target from $122 to $125
  • Citigroup lowers Domino’s Pizza (NYSE:DPZ) price target from $431 to $398

Recent Comments

No comments to show.

Copyright © 2023 DD STOCK.

Powered by PressBook Child WordPress theme